After receiving the prestigious “Seal of Excellence” from the European Commission on October 23, 2018, Glycanostics' next submission, to the Horizon 2020 Programme, won a € 50 000 grant. The Horizon 2020 Programme for Research and Innovation 2014-2020 aims to support excellent science, industrial leadership and social impact startups. Its main goal is to ensure that European countries produce world-class scientific breakthroughs, remove barriers to innovation, and make it easier for public and private sectors to work together in bringing innovations to market.
Jan Tkac, Сo-Founder and Executive Manager of Glycanostics Ltd., comments:
“Funding always helps to speed up the development process. We applied for the EU grant with a specific focus in mind— to support the technological and clinical validation stages of our project. We will also use it for further product development, for the certification process, and to build up our business team.“
The Horizon 2020 “Seal of Excellence” and the recently awarded grant again confirm the innovative potential of Glycanostics’ products as well as the efficiency of its business model for meeting current market needs. The Glycanostics’ team will apply for the SME Instrument Phase 2 project in the near future, but will focus on current technology validation and IP-rights protection in the meantime.
Horizon 2020 is the largest research and innovation program in the EU, with nearly €80 billion of funding available over 7 years (2014 to 2020), in addition to the private investments this money will attract. The program aims to support researchers, organizations, and entrepreneurs, with the goal to aid promising breakthroughs and discoveries. Seen as a means to drive economic growth and create jobs, Horizon 2020 has the political backing of Europe’s leaders and the Members of the European Parliament. They agreed that research is an investment in our future, and so put it at the heart of the EU’s blueprint for smart, sustainable, and inclusive growth and jobs.
This project received the highest scores for its proposal in the extremely competitive evaluation process.
Glycanostics was chosen as a finalist in the Grand Finale with five other remarkable startups.
The application covering Glycanostics' diagnostic method is currently filed in two patent offices in Europe and Luxemburg.
Glycanoctics innovations are again supported and highly ranked by leading industry experts. This time the company won the European Research Council (ERC) Proof of Concept Grant.
The competition's objectives are to actively support innovative projects with high market potential
In April 2018 the technology validation was successfully completed indicating a great potential of Glycanostics innovative products for prostate cancer (PCa) diagnostics.
Glycanostics is an innovative start-up company established in 2017 to bring its revolutionary cancer diagnostics products to the US and EU markets.